title: 99mTc-ECD brain perfusion SPECT in hyperalgesic fibromyalgia.
abstract: OBJECTIVE
  Neuro-imaging studies with (99m)Tc-HMPAO SPECT in fibromyalgia (FM) patients have reported only limited subcortical hypoperfusion. (99m)Tc-ECD SPECT is known to provide better evaluation of areas of high cerebral blood flow and regional metabolic rate. We evaluated a homogeneous group of hyperalgesic patients with FM using (99m)Tc-ECD SPECT. The aim of this study was to investigate brain processing associated with spontaneous pain in FM patients.
  
  
  METHODS
  Eighteen hyperalgesic FM women (mean age 49 years, range 25-63 years; American College of Rheumatology criteria) and ten healthy women matched for age were enrolled in the study. A voxel-by-voxel group analysis was performed using SPM2 (p<0.05, corrected for multiple comparisons). Visual Analogue Scale score for pain was 82+/-4 at the time of the SPECT study.
  
  
  RESULTS
  Compared with control subjects, we observed individual brain SPECT abnormalities in FM patients, confirmed by SPM2 analysis, with hyperperfusion of the somatosensory cortex and hypoperfusion of the frontal, cingulate, medial temporal and cerebellar cortices.
  
  
  CONCLUSIONS
  In the present study, performed without noxious stimuli in hyperalgesic FM patients, we found significant hyperperfusion in regions of the brain known to be involved in the sensory dimension of pain processing and significant hypoperfusion in areas assumed to be associated with the affective-attentional dimension. As current pharmacological and non-pharmacological therapies act differently on the two components of pain, we hypothesise that SPECT could be a valuable and readily available tool to guide individual therapeutic strategy and provide objective follow-up of pain processing recovery under treatment.
authors.affiliation: Service Central de Biophysique et de Médecine Nucléaire, Assistance Publique des Hôpitaux de Marseille, Centre Hospitalo-Universitaire de la Timone, 264 rue Saint Pierre, 13385, Marseille Cedex 05, France. eric.guedj@ap-hm.fr
authors.forename: Eric
authors.initials: E
authors.lastname: Guedj
authors.forename: David
authors.initials: D
authors.lastname: Taieb
authors.forename: Serge
authors.initials: S
authors.lastname: Cammilleri
authors.forename: David
authors.initials: D
authors.lastname: Lussato
authors.forename: Catherine
authors.initials: C
authors.lastname: de Laforte
authors.forename: Jean
authors.initials: J
authors.lastname: Niboyet
authors.forename: Olivier
authors.initials: O
authors.lastname: Mundler
mesh_terms: D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging*; D003545:Cysteine / Q000031:analogs & derivatives*; D005260:Female; D005356:Fibromyalgia / Q000150:complications* / Q000000981:diagnostic imaging*; D006801:Humans; D006930:Hyperalgesia / Q000000981:diagnostic imaging* / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D015609:Organotechnetium Compounds; D010477:Perfusion / Q000379:methods; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
chemical_list: D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C059659:technetium Tc 99m bicisate; D003545:Cysteine